Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $68M | $-425M | $-413M | $-396M | -61.5% | 16.9% | -20.5% |
| 2024 | $58M | $-524M | $-519M | $-355M | -59.5% | 59.6% | 7.9% |
| 2023 | $36M | $-506M | $-481M | $-408M | -45.8% | -30.4% | 1.5% |
| 2022 | $52M | $-451M | $-474M | $-392M | -38.4% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 52.12 | 36.28 | 57.88 | 67.67 |
| Operating Revenue | - | 52.12 | 36.28 | 57.88 | 67.67 |
| Operating Expense | - | 510.28 | 551.57 | 592.14 | 508.66 |
| Research And Development | - | 419.98 | 435.07 | 466.31 | 388.86 |
| Selling General And Administration | - | 90.31 | 116.50 | 125.83 | 119.80 |
| Total Expenses | - | 510.28 | 551.57 | 592.14 | 508.66 |
| Operating Income | - | -458.16 | -515.29 | -534.26 | -440.99 |
| Total Operating Income As Reported | - | -458.16 | -515.29 | -534.26 | -440.99 |
| EBITDA | - | -450.59 | -506.32 | -523.98 | -425.07 |
| Normalized EBITDA | - | -437.11 | -506.22 | -491.41 | -424.17 |
| EBIT | - | -458.16 | -515.29 | -534.26 | -440.99 |
| Interest Income | - | 8.54 | 49.83 | 47.81 | 29.20 |
| Net Interest Income | - | 8.54 | 49.83 | 47.81 | 29.20 |
| Other Income Expense | - | -24.56 | -15.73 | -32.56 | -0.90 |
| Interest Income Non Operating | - | 8.54 | 49.83 | 47.81 | 29.20 |
| Net Non Operating Interest Income Expense | - | 8.54 | 49.83 | 47.81 | 29.20 |
| Pretax Income | - | -474.19 | -481.19 | -519.02 | -412.69 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income From Continuing And Discontinued Operation | - | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income From Continuing Operation Net Minority Interest | - | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income | - | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income Common Stockholders | - | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income Including Noncontrolling Interests | - | -474.19 | -481.19 | -519.02 | -412.69 |
| Normalized Income | - | -460.70 | -481.09 | -486.46 | -411.80 |
| Diluted NI Availto Com Stockholders | - | -474.19 | -481.19 | -519.02 | -412.69 |
| Basic Average Shares | - | 76.97 | 88.77 | 98.85 | 108.38 |
| Diluted Average Shares | - | 76.97 | 88.77 | 98.85 | 108.38 |
| Reconciled Depreciation | - | 7.57 | 8.98 | 10.28 | 15.92 |
| Total Unusual Items | - | -13.48 | -0.10 | -32.56 | -0.90 |
| Total Unusual Items Excluding Goodwill | - | -13.48 | -0.10 | -32.56 | -0.90 |
| Special Income Charges | - | -13.48 | -0.10 | 0 | 0 |
| Restructuring And Mergern Acquisition | - | 13.48 | 0.10 | 0 | 0 |
| Gain On Sale Of Security | - | - | - | -32.56 | -0.90 |
| General And Administrative Expense | - | 90.31 | 116.50 | 125.83 | 119.80 |
| Other Gand A | - | 90.31 | 116.50 | 125.83 | 119.80 |
| Earnings From Equity Interest | - | -11.08 | -15.63 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Intellia Therapeutics, Inc.this co. | NTLA | $2.1B | - | 3.07 | -61.5% | - |
| Kodiak Sciences Inc. | KOD | $2.1B | - | 13.58 | -146.1% | - |
| Aurinia Pharmaceuticals Inc. | AUPH | $2.1B | 7.33 | 3.62 | 49.4% | 15.22 |
| Clover Health Investments, Corp. | CLOV | $2.1B | -24.56 | 6.81 | -27.7% | - |
| NovoCure Limited | NVCR |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $2.1B |
| - |
| 6.12 |
| -40.0% |
| - |
| Recursion Pharmaceuticals, Inc. | RXRX | $2.0B | -3.13 | 1.78 | -57.0% | -2.42 |
| Progyny, Inc. | PGNY | $2.0B | 34.11 | 3.87 | 11.3% | 21.18 |
| Omnicell, Inc. | OMCL | $2.0B | 967.26 | 1.61 | 0.2% | 21.53 |
| Trevi Therapeutics, Inc. | TRVI | $2.0B | -46.25 | 10.79 | -23.3% | -45.92 |
| Peer Median | - | 2.10 | 4.99 | -25.5% | 15.22 | |
Historically, Jun has averaged the highest return (+33.2%); Oct the lowest (-17.0%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +46.3%Positive MonthJan 2026: +46.27% | +4.8%Positive MonthFeb 2026: +4.79% | -7.0%Negative MonthMar 2026: -6.97% | +5.1%Positive MonthApr 2026: +5.15% | +4.4%Positive MonthMay 2026: +4.38% | +20.3%Positive MonthJun 2026: +20.26% | -36.9%Negative MonthJul 2026: -36.88% | +24.3%*Positive MonthAug 2026: +24.34% | — | — | — | — |
| 2025 | -11.5%Negative MonthJan 2025: -11.49% | -2.2%Negative MonthFeb 2025: -2.23% | -29.5%Negative MonthMar 2025: -29.53% | +24.8%Positive MonthApr 2025: +24.75% | -22.5%Negative MonthMay 2025: -22.55% | +36.5%Positive MonthJun 2025: +36.54% | +24.1%Positive MonthJul 2025: +24.09% | -2.4%Negative MonthAug 2025: -2.45% | +52.1%Positive MonthSep 2025: +52.09% | -26.9%Negative MonthOct 2025: -26.93% | -28.8%Negative MonthNov 2025: -28.76% | +0.0%Neutral MonthDec 2025: +0.00% |
| 2024 | -21.9%Negative MonthJan 2024: -21.88% | +34.8%Positive MonthFeb 2024: +34.84% | -14.4%Negative MonthMar 2024: -14.35% | -22.2%Negative MonthApr 2024: -22.21% | -0.1%Neutral MonthMay 2024: -0.09% | +4.7%Positive MonthJun 2024: +4.68% | +17.1%Positive MonthJul 2024: +17.11% | -14.4%Negative MonthAug 2024: -14.38% | -8.4%Negative MonthSep 2024: -8.42% | -30.8%Negative MonthOct 2024: -30.80% | +9.8%Positive MonthNov 2024: +9.85% | -25.4%Negative MonthDec 2024: -25.35% |
| 2023 | +21.6%Positive MonthJan 2023: +21.64% | -5.3%Negative MonthFeb 2023: -5.35% | -7.2%Negative MonthMar 2023: -7.22% | +1.3%Neutral MonthApr 2023: +1.29% | -1.3%Neutral MonthMay 2023: -1.30% | +9.4%Positive MonthJun 2023: +9.45% | +3.8%Positive MonthJul 2023: +3.80% | -11.5%Negative MonthAug 2023: -11.46% | -15.6%Negative MonthSep 2023: -15.64% | -20.8%Negative MonthOct 2023: -20.78% | +18.3%Positive MonthNov 2023: +18.28% | +2.9%Positive MonthDec 2023: +2.90% |
| 2022 | -20.0%Negative MonthJan 2022: -20.02% | +4.5%Positive MonthFeb 2022: +4.53% | -26.5%Negative MonthMar 2022: -26.48% | -32.5%Negative MonthApr 2022: -32.53% | -5.9%Negative MonthMay 2022: -5.89% | +12.2%Positive MonthJun 2022: +12.18% | +25.1%Positive MonthJul 2022: +25.12% | -7.3%Negative MonthAug 2022: -7.26% | -6.8%Negative MonthSep 2022: -6.83% | -5.7%Negative MonthOct 2022: -5.68% | -2.5%Negative MonthNov 2022: -2.50% | -32.2%Negative MonthDec 2022: -32.20% |
| 2021 | — | — | — | — | -2.4%Negative MonthMay 2021: -2.38% | +116.1%Positive MonthJun 2021: +116.05% | -12.4%Negative MonthJul 2021: -12.39% | +13.2%Positive MonthAug 2021: +13.17% | -16.4%Negative MonthSep 2021: -16.43% | -0.9%Neutral MonthOct 2021: -0.87% | -13.5%Negative MonthNov 2021: -13.51% | +2.8%Positive MonthDec 2021: +2.81% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
